Thalassemia & Sickle Cell Center

Thalassemia & Sickle Cell Center

Comprehensive Care for Thalassemia & Sickle Cell Disease —From Infancy Through Adulthood.

Transfusion, chelation, curative stem‑cell transplant, and cutting‑edge gene therapy delivered by one coordinated team.

The Thalassemia & Sickle Cell Center at Burjeel Medical City provides comprehensive care, from early detection through advanced disease management. Services include newborn screening, transfusion protocols, stroke prevention with TCD screening, disease-modifying therapies (hydroxyurea, voxelotor, crizanlizumab, luspatercept), and curative allogeneic stem-cell transplants. Our team also offers haploidentical and cord-blood transplants, gene-addition therapies, and gene-editing treatments.

1,250

thalassemia & sickle-cell patients under active follow-up (2024)

8,900+

red-cell transfusions and 12,400 apheresis sessions annually

150+

curative stem-cell transplants with a 92% event-free survival rate

First

Middle-Eastern site for CRISPR-Cas9 β-thalassemia gene-editing trials

Common Conditions & Subspecialty Clinics.

  • Individualized chronic and acute pain management plans 
  • Cognitive-behavioral therapy (CBT) 
  • Opioid stewardship and risk mitigation 
  • Advocacy in school and workplace settings 

  • Joint pediatric-adult visits between ages 14–18 
  • Education for self-management and independence 
  • Vocational and life-skill counseling 

  • Lentiviral β-globin gene addition therapy 
  • CRISPR-Cas9 gene editing targeting BCL11A 
  • Long-term registry follow-up for clinical trial participants 

  • Matched sibling, unrelated donor, and haploidentical bone marrow transplant (BMT) 
  • Post-transplant cyclophosphamide for GVHD prophylaxis 

  • Hydroxyurea dose optimization 
  • Monthly simple transfusion or exchange apheresis 
  • Acute pain management pathway and VOC crisis unit 
  • Stroke prevention with transcranial Doppler (TCD) screening 

  • Regular transfusions with pre-storage filtered and leukodepleted red cells 
  • Liver iron concentration (LIC)-guided iron chelation therapy 
  • Endocrine and cardiac monitoring 
  • Growth and fertility clinics for long-term care 

Procedures & Treatments.

MRI T2 Cardiac & LIC Monitoring every 12 months

Iron-Chelation Therapy: Deferasirox, deferiprone, desferrioxamine pump

Automated Red-Cell Exchange (Apheresis) for SCD stroke prevention and pregnancy

Phenotype-matched, leucoreduced packed RBC transfusions every 3–4 weeks (target Hb 9–10.5 g/dL)

Allogeneic Stem-Cell Transplant with myeloablative or reduced-intensity regimens

Crizanlizumab & Voxelotor for VOC reduction and Hb improvement in SCD

Luspatercept for non-transfusion-dependent β-thalassemia

Hydroxyurea dose escalation per AUC with monthly lab monitoring

CRISPR-Cas9 gene-editing targeting BCL11A erythroid enhancer (Phase III)

Bluebird HGB-212 lentiviral gene therapy (ongoing trial)

Vaccination: PCV13/23, MenACWY, Hib, HBV boosters, influenza

Fertility preservation—sperm/oocyte cryopreservation prior to BMT

Endocrine panel: thyroid, glucose tolerance, vitamin D, sexual maturation

Echocardiography & pulmonary-artery pressure screening annually

TCD ultrasound annually for ages 2–16

Care Pathway & Coordination.

1
Comprehensive Intake & Baseline Labs

Comprehensive Intake & Baseline Labs

CBC, Hb electrophoresis, ferritin, MRI, TCD screening

2

Personalized Management Plan

Personalized Management Plan

Tailored transfusion & chelation schedule, hydroxyurea or luspatercept initiation

3

Multidisciplinary Review

Multidisciplinary Review

Hematology, cardiology, endocrine, psychology every 6 months

4

Curative Therapy Evaluation

Curative Therapy Evaluation

HLA typing, donor search, gene-therapy trial screening

5

Transition to Adult Services

Transition to Adult Services

Joint clinic and self-management toolkit

6

Lifelong Monitoring & Wellness

Lifelong Monitoring & Wellness

Annual assessments and rapid escalation for complications

Technology & Facilities.

Dedicated Day-Hosp Infusion & Pain Unit

Rapid VOC management with goal-oriented analgesia

Apheresis & Cell-Processing Lab

Automated red-cell exchange and stem-cell collection

3-T MRI T2 & FerriScan LIC Analysis

Non-invasive iron quantification

GMP Gene-Therapy Clean Room

Viral-vector transduction and CRISPR editing for gene therapies

Digital Adherence App

Medication reminders, VOC diary, and telehealth portal

Family & Patient Education Center

Peer support groups, counseling, and workshops

Patient Stories.

Click Here
A Healing Journey At Burjeel Cancer Institute

A Healing Journey At Burjeel Cancer Institute

Bassam

Multiple Myeloma

Click Here
Welcoming Our Little Warrior

Welcoming Our Little Warrior

Maryam Violeta

Spina Bifida Surgery In The Womb

Frequently Asked Questions.

1. How often will my child need transfusions?

Typically, transfusions are needed every 3–4 weeks to maintain safe hemoglobin levels, but this can be adjusted based on individual needs.

2. Is stem-cell transplant risky?

Stem-cell transplants offer more than a 90% cure rate with matched donors. While risks like GVHD and infection exist, our team uses modern protocols to mitigate these risks.

3. What is gene-editing therapy?

Gene-editing involves modifying stem cells outside the body using CRISPR to reactivate fetal hemoglobin, potentially allowing patients to live without transfusions.

4. How do you manage pain crises?

We follow evidence-based protocols, using opioids and additional medications, hydration, and home pain management strategies.

Ready to Start Your Health Journey?

Take the first step towards better health with our expert team.

Book Appointment Contact Us